PIM1 Is a Potential Therapeutic Target for the Leukemogenic Effects Mediated by JAK/STAT Pathway Mutations in T-ALL/LBL

The authors combined the analysis of molecular data from T-ALL/LBL patients with the generation of hematopoietic cellular models to reveal that JAK/STAT pathway mutations are associated with an aberrant transcriptional profile.